Trial · NCT02247375
Registered outcomes23
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 23
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Changes from baseline in Mac-1 expression | Pre-dose, up to day 14 after start of treatment | |
| Primary | Plasma concentrations of BIIL 284 BS, BIIL 260 BS, BIIL 315 ZW and BIIL 304 ZW | Pre-dose, up to day 14 after start of treatment | |
| Primary | Maximum concentration of the analyte in plasma (Cmax) | Pre-dose, up to day 14 after start of treatment | |
| Primary | Trough concentration of the analyte in plasma shortly before drug administration in a steady state dosing interval (Cpre,ss) | Pre-dose, up to day 14 after start of treatment | |
| Primary | Time to reach the maximum concentration of the analyte in plasma (tmax) | Pre-dose, up to day 14 after start of treatment | |
| Primary | Area under the concentration-time curve of the analyte in plasma (AUC) | Pre-dose, up to day 14 after start of treatment | |
| Primary | Number of patients with adverse events | Up to 4 weeks | |
| Primary | Global assessment of tolerability by the patient on a 4-point scale | Up to 14 days after start of treatment | |
| Primary | Global assessment of tolerability by investigator on a 4-point scale | Up to 14 days after start of treatment | |
| Secondary | Changes from baseline in tender joint count (TJC) | Pre-dose, up to day 14 after start of treatment | Bilateral assessment of twenty-eight joints by e.g., pressure, joint manipulation etc. |
| Secondary | Changes from baseline in swollen joint count (SJC) | Pre-dose, up to day 14 after start of treatment | Twenty-eight joints were bilaterally assessed whether they are swollen or not |
| Secondary | Changes from baseline in patient's current pain level assessment by visual analogue scale (VAS) | Pre-dose, up to day 14 after start of treatment | |
| Secondary | Changes from baseline in patient's global assessment of disease activity by VAS | Pre-dose, up to day 14 after start of treatment | |
| Secondary | Global assessment of disease activity by investigator on a 5-point scale | Up to 14 days after start of treatment | |
| Secondary | Changes from baseline for patient's assessment of physical function | Pre-dose, up to day 14 after start of treatment | Functional disability was measured using the disability section of the Health Assessment Questionnaire (HAQ) |
| Secondary | Changes from baseline in erythrocyte sedimentation rate (ESR) | Pre-dose, up to day 14 after start of treatment | |
| Secondary | Changes from baseline in C-reactive protein (CRP) | Pre-dose, up to day 14 after start of treatment | |
| Secondary | Changes from baseline in american college of rheumatology (ACR) 20 score | Pre-dose, up to day 14 after start of treatment | |
| Secondary | Changes from baseline in disease activity score (DAS) | Pre-dose, up to day 14 after start of treatment | |
| Secondary | Global efficacy assessment by the patient on a 4-point scale | Up to 14 days after start of treatment |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02247375/registered